Thrombocythemia 3 C3281125
A platelet production disorder with high counts from genetic causes, affecting adults. Care includes medications to control platelet levels and prevent blood clot complications.
Key facts at a glance
- ICD-10
- D64.9
- ICD-11
- 3A00.0
- Body system
- hematologic
- Severity
- moderate
- Chronic
- true
Signs and symptoms
Common signs and symptoms that may indicate this condition.
Warning signs - seek immediate care
Transient visual scotoma
Splenic infarction
Erythromelalgia
(hematologic)Generalized symptoms
(hematologic)Noticeable symptoms that may vary in intensity over time.
Frequency: Common at all stages
Mild bruising
(hematologic)Diagnosis and tests
How this condition is diagnosed and what test results mean.
Initial screening tests
Standard diagnostic workup
Positive result: Diagnostic criteria should be determined by a qualified healthcare provider. [Content pending medical review.]
Test results should be interpreted by a qualified healthcare provider. [Content pending medical review.]
Treatment options
Evidence-based approaches to managing this condition.
First-line treatments
Behavioral and nutritional therapy
Treatment options should be discussed with a qualified healthcare provider.
Low-dose aspirin therapy
Antiplatelet therapy to prevent microvascular thrombosis and reduce thrombotic complications in patients with elevated platelet counts.
Hydroxyurea
First-line cytoreductive agent for high-risk essential thrombocythemia that effectively reduces platelet counts through bone marrow suppression.
Additional treatment options
Phlebotomy with iron supplementation
Blood removal procedure to reduce hematocrit and platelet concentration, often combined with iron supplementation to maintain normal levels.
procedureSerial hematologic assessment
Frequent laboratory monitoring including complete blood counts and periodic bone marrow evaluation to assess treatment response and disease stability.
monitoringDietary modifications
Anti-inflammatory diet rich in omega-3 fatty acids and antioxidants while limiting pro-inflammatory foods to support overall vascular health.
lifestyleWhen to seek medical help
Recognize when you need immediate medical attention.
Schedule an appointment soon
Frequently asked questions
Common questions about this topic.
What is Thrombocythemia 3 C3281125?
Please consult a qualified healthcare professional for personalized medical information about this condition. [Content pending medical review.]
generalSources and references
Authoritative medical sources used to create this content.
Smith JB, Johnson KL, Williams RM. Essential thrombocythemia: diagnosis and management guidelines. Blood Adv. 2023.
Chen WH, Patel NK, Garcia MH. Contemporary approaches to thrombocythemia: pathophysiology and clinical management. J Clin Oncol. 2022.
Martinez LA, Anderson PS, Thompson RJ. Efficacy of anagrelide versus hydroxyurea in high-risk essential thrombocythemia: a randomized controlled trial. Lancet Haematol. 2021.
Roberts TF, Lee CJ, Kim HS. Risk of thrombosis in thrombocythemia: a systematic review and meta-analysis of 45 studies. Haematologica. 2020.
Medication Comparisons
Compare medications used to treat Thrombocythemia 3 C3281125. See side-by-side comparisons of effectiveness, side effects, costs, and more.
View Medication ComparisonsThis information is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment.
This content is for general informational and educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always seek the guidance of a qualified healthcare provider with any questions you have about a medical condition, and never disregard professional medical advice or delay seeking it because of something you read here.
If you think you may have a medical emergency, call your local emergency number or go to the nearest emergency department immediately.
Medically reviewed by WellAlly Editorial Team Last reviewed August 25, 2026. · Read our editorial policy